Legal Representation
Attorney
Rachel Turow
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 17, 2008 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Jan 17, 2008 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Jun 20, 2007 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 20, 2007 | RFTP | Z | REMOVED FROM TEAS PLUS | Loading... |
| Jun 20, 2007 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 20, 2007 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 20, 2007 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 13, 2007 | MDSC | O | NOTICE OF DESIGN SEARCH CODE MAILED | Loading... |
| Mar 12, 2007 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Cardiovascular pharmaceuticals
First Use Anywhere:
May 18, 2006
First Use in Commerce:
May 19, 2006
Additional Information
Design Mark
The mark consists of The word REMODULIN in red with the words (treprostinil sodium) Injection in smaller letters below it, also in red, and two swooshes above it, one red, one blue. .
Color Claim
The applicant claims color as a feature of the mark, namely, red and blue.
Classification
International Classes
005